panitumumab
amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
new 1l in ras wt mcrc based on os and pfs benefit in ph3rct paradigm #plenary #asco22 presented by dr yoshino 
Regional Cancer Research Director @CleveClinicFl #Scientist #Immune #Oncology #Epigenetics #Cancer #Sensitisation #TIME #StayPositive. Tweets are mine.